BIIE-0246

BIIE-0246
Identifiers
Synonyms BIIE-0246
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
Chemical and physical data
Formula C49H57N11O6
Molar mass 896.045 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

BIIE-0246 is a drug used in scientific research which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y2.[1] It was one of the first non-peptide Y2-selective antagonists developed, and remains among the most widely used tools for studying this receptor. It has been used to demonstrate a role for the Y2 subtype as a presynaptic autoreceptor limiting further neuropeptide Y release,[2][3] as well as modulating dopamine[4] and acetylcholine release.[5] It has also been shown to produce several behavioural effects in animals, including reducing alcohol consumption in addicted rats[6][7] and anxiolytic effects,[8] although while selective Y2 agonists are expected to be useful as anorectics,[9][10] BIIE-0246 did not appear to increase appetite when administered alone.[11]

References

  1. ↑ Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K (November 1999). "BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist". European Journal of Pharmacology. 384 (2-3): R3–5. PMID 10611450. doi:10.1016/S0014-2999(99)00650-0.
  2. ↑ King PJ, Williams G, Doods H, Widdowson PS (May 2000). "Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release". European Journal of Pharmacology. 396 (1): R1–3. PMID 10822055. doi:10.1016/S0014-2999(00)00230-2.
  3. ↑ Malmström RE, Lundberg JO, Weitzberg E (March 2002). "Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y(2) receptor evidenced by BIIE0246". European Journal of Pharmacology. 439 (1-3): 113–9. PMID 11937100. doi:10.1016/S0014-2999(02)01371-7.
  4. ↑ Adewale AS, Macarthur H, Westfall TC (May 2007). "Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors". Neuropharmacology. 52 (6): 1396–402. PMID 17382974. doi:10.1016/j.neuropharm.2007.01.018.
  5. ↑ Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ (March 2008). "Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway". Journal of Molecular and Cellular Cardiology. 44 (3): 477–85. PMID 17996892. doi:10.1016/j.yjmcc.2007.10.001.
  6. ↑ Thorsell A, Rimondini R, Heilig M (October 2002). "Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats". Neuroscience Letters. 332 (1): 1–4. PMID 12377370. doi:10.1016/S0304-3940(02)00904-7.
  7. ↑ Rimondini R, Thorsell A, Heilig M (February 2005). "Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence". Neuroscience Letters. 375 (2): 129–33. PMID 15670655. doi:10.1016/j.neulet.2004.10.084.
  8. ↑ Bacchi F, Mathé AA, Jiménez P, Stasi L, Arban R, Gerrard P, Caberlotto L (December 2006). "Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze". Peptides. 27 (12): 3202–7. PMID 16959374. doi:10.1016/j.peptides.2006.07.020.
  9. ↑ Félétou M, Levens NR (October 2005). "Neuropeptide Y2 receptors as drug targets for the central regulation of body weight". Current Opinion in Investigational Drugs (London, England : 2000). 6 (10): 1002–11. PMID 16259221.
  10. ↑ Parker SL, Balasubramaniam A (February 2008). "Neuropeptide Y Y2 receptor in health and disease". British Journal of Pharmacology. 153 (3): 420–31. PMC 2241788 Freely accessible. PMID 17828288. doi:10.1038/sj.bjp.0707445.
  11. ↑ Scott V, Kimura N, Stark JA, Luckman SM (July 2005). "Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour". Journal of Neuroendocrinology. 17 (7): 452–7. PMID 15946163. doi:10.1111/j.1365-2826.2005.01330.x.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.